Press Release for the Quarter ended 30th June, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanjivani Paranteral Ltd reported its Q1FY26 results with revenue from operations growing 8.9% year-on-year to Rs. 178.9 million. EBITDA margin expanded slightly to 15.0% from 14.7% a year ago, while Profit After Tax rose marginally by 1.0% to Rs. 17.3 million. The injectables segment was the standout performer with 47.1% YoY growth to Rs. 89.9 million, while the oral segment declined 11.1% YoY to Rs. 88.2 million due to shipment-related challenges. Exports accounted for 73.7% of total revenue, with core markets including CIS, Middle East, Africa, and Latin America driving the bulk of business.
A modest quarter with mixed signals – strong injectables growth and stable margins are positive, but weakness in the oral segment and only marginal PAT growth suggest near-term pressure. The continued export dependence (73.7%) also keeps the company exposed to global trade uncertainties, which the management has acknowledged.